Burden of Disease
The epidemiological data used in the model are derived from a study of 12 Istanbul hospitals [2] , which cover 65% of the overall Istanbul population of 13 million. This, in turn, represents 19% of the overall Turkish population of 70 million.
The annualized rate of pneumococcal meningitis in children younger than 5 years is between 3 and 5 per 100,000, for pneumococcal septicemia 7.5 to 22.5 per 100,000, for hospitalized (average 6 days) and community suspected pneumococcal pneumonia between 210 and 2790 per 100,000, for all-cause otitis media 330 per 1000, and for pneumococcal otitis media 58 per 1000.
Vaccine Efficacy
The efficacy of 7-valent pneumococcal conjugate vaccine (PCV) and of 13-valent PCV against invasive pneumococcal disease (IPD) was assumed to be at the lower end of the 95% confidence interval (83%) [4] , for suspected pneumococcal pneumonia 20.5% [6] , and for all-cause otitis media 6% [7] . The efficacy of 10-valent PCV against IPD was assumed to be at the lower end of the 95% confidence interval (83%) [5] . Its efficacy for suspected pneumococcal pneumonia was assumed to be 20.5% and for pneumococcal otitis media 41.4% [3] . While longer-term vaccine effectiveness for all indications was assumed to be of at least 5 years' duration [11] , vaccine effectiveness was assumed to decrease at a rate of 2% every 6 months; by age 5 years, the effectiveness was assumed to have decreased by 18% [8] .
Serotype Coverage and Serotype-Specific Efficacy
The serotype coverage for infants and children in Turkey for 13-valent PCV was taken to be 74%, for 10-valent PCV 61%, and for 7-valent PCV 38% [9] . The serotype-specific age-specific vaccine efficacy for IPD reduces to 26% at 60 months for 7-valent PCV, to 42% for 10-valent PCV, and to 51% for 13-valent PCV.
Herd Protection
Not incorporated.
Cost of Disease Treatment
All the disease treatment costs are local costs (converted to 2011 US$). Only direct costs were applied. The cost of treating a pediatric patient with pneumococcal bacteremia/septicemia was US $500 and for pneumococcal meningitis, US $1000 [2] . The cost of treating suspected pneumococcal pneumonia is made up of 7500 hospitalized cases at US $325 per case and 142,500 outpatient cases at US $25 to US $60, with an average of US $40.50 per case [2] . The average cost of treating a case of pediatric otitis media was US $30 [10] .
Cost of Disease Sequelae
The long-term cost of treating deafness, focal neurological signs, and chronic seizures following pneumococcal meningitis, occurring at rates of 15.5% [12] , 6% [13] , and 7% [14] respectively, was taken as one tenth the cost of treating such sequelae in the United Kingdom [1] based on the relative per-capita gross domestic products (GDPs) of Turkey and the United Kingdom, and was on average US $1700 per child with long-term sequelae. The cost of a death was US $160.
Mortality
For pneumococcal meningitis, there would be 17 deaths in a total of 555 cases, giving a case-fatality rate of 3.4% for those up to 24 months of age and 2.5% thereafter. For pneumococcal bacteremia/septicemia, there would be 7 deaths in a total of 264 cases, giving a case-fatality rate of 2.6%. The number of deaths due to suspected pneumococcal pneumonia is derived from the 13,253 deaths due to all causes reported in Turkey in the 7.794 million infants and children younger than 5 years [15] . Of these deaths, 1855 (14%) are reported to be due to suspected pneumococcal pneumonia. There would be a total of 150,020 cases of suspected pneumococcal pneumonia, thus giving an average case-fatality rate of 1.2%. This is lower than the pneumococcal pneumonia case-fatality rate of 6% for the Eastern Mediterranean region as reported in the Pneumococcal Global Burden of Disease study [16] . There would be no deaths attributed to otitis media. IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.
Discounting
Future health care costs were discounted at a rate of 3%. Some models also discount future benefits [17] . We performed a sensitivity analysis with a 6% discounting of future benefits.
Vaccine Cost, Schedule, and Vaccination Coverage
The cost of each dose of vaccine was taken to be US $30 plus an administration cost of US $3.26 for each dose, in a fourdose schedule and with 86% vaccine coverage in the population.
Cost-Effectiveness
A calculation of the mean cost of managing cases was performed for a vaccinated and an unvaccinated population. The results were expressed as cost per life-year gained and compared against World Health organization cost-effectiveness thresholds of "very NA, not applicable/available; OM, otitis media; PCV, pneumococcal conjugate vaccine.
cost-effective" being 1 Â per-capita GDP (US $10,471 in Turkey) and "cost effective" being 3 Â per-capita GDP [18] .
Sensitivity Analysis
Given that the model is a cohort model and not a Monte Carlo simulation, we chose to perform a one-way sensitivity analysis rather than a probabilistic sensitivity analysis.
Results
The results are shown in Table 2 . The base-case cost per lifeyear gained would be US $7109, US $6784, and US $6696 for 7-valent, 10-valent, and 13-valent PCV, respectively. The cost of a national immunization program using any of the vaccines would be US $160 million. Using the World Health organization threshold, the implementation of a universal state-funded pediatric vaccination program using any PCV in Turkey is very cost-effective.
Sensitivity Analysis
The sensitivity analysis is shown in Table 3 . The vaccine efficacy against suspected pneumococcal pneumonia, based on that for the Northern California Kaiser Permanente study [6] , has the greatest impact on the results. If the efficacy of the vaccine was only 4.4%, the lower end of the 95% confidence interval, then the vaccine would cease to be very cost-effective but would remain cost-effective. Increasing the vaccine cost by 50% (to US $45) still renders the vaccines very cost-effective. Changing all the parameters to the "least favorable" pushes the vaccines just beyond the cost-effectiveness threshold.
The cost per life-year gained is below the 1 Â per-capita GDP thresholds across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.
Discussion
The main finding of this analysis is that any PCV would appear to be a very cost-effective intervention in the context of a national pediatric immunization schedule in Turkey, even without accounting for the added benefits of herd protection and other indirect effects such as societal savings. The main strengths of the analysis reside in the inclusion of predominantly local data and the use of an internationally recognized cost-effectiveness yardstick.
There is an inherent weakness in the way the national figures are derived in the present analysis in that the 12 Istanbul hospitals may not be representative of hospitals in the wider country and small inaccuracies in data at the 12 hospitals can be magnified into larger inaccuracies at a national level. The inclusion of UK incidence rates and costs, as well as the sensitivity analysis, provides a degree of confidence that such inaccuracies, if they exist, do not affect the results in a fundamental way.
The rates of pneumococcal infection used in the present analysis are either comparable to or less than those calculated and recently published for the Eastern Mediterranean Region [16] . The consequences for the present study are that the results are likely to be more conservative than if a global estimate were to be used, and the results reflect what may be monitored in Turkey after the introduction of the vaccine.
For different regions of Turkey, the GINI coefficient, a measure of equality, suggests that within the different regions of Turkey there is inequality, but that the inequality is distributed evenly [19] . We believe that the Turkish national data on health care and the GINI coefficients provide a degree of confidence that our results are applicable to Turkey as an entity. Although it is difficult to compare cost-effectiveness across different therapeutic areas but using different measures, we have noted that the cost per disability-adjusted life-year in Turkey for the treatment of lung cancer is US $6141 and for hepatitis C treatment US $6638. Treatment for these conditions in Turkey is funded by the state.
A number of studies performed in countries with a socioeconomic background similar to that of Turkey also conclude that PCV would be cost-effective using direct medical costs (Colombia [20] , Brazil [21] , Taiwan [22] , Malaysia [23] , Argentina [24] , and Uruguay [25] ) or even cost-saving with the inclusion of societal costs (Mexico [26] ).
In conclusion, it appears that any PCV, according to internationally accepted criteria, would be very cost-effective in a national Turkish pediatric immunization schedule.
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